Logo image of BIOL

BIOLASE INC (BIOL) Stock Fundamental Analysis

NASDAQ:BIOL - Nasdaq - US0909117022 - Common Stock - Currency: USD

0.129  -0.02 (-13.19%)

After market: 0.109 -0.02 (-15.5%)

Fundamental Rating

1

Overall BIOL gets a fundamental rating of 1 out of 10. We evaluated BIOL against 187 industry peers in the Health Care Equipment & Supplies industry. BIOL may be in some trouble as it scores bad on both profitability and health. BIOL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIOL had negative earnings in the past year.
In the past year BIOL has reported a negative cash flow from operations.
In the past 5 years BIOL always reported negative net income.
BIOL had a negative operating cash flow in each of the past 5 years.
BIOL Yearly Net Income VS EBIT VS OCF VS FCFBIOL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -111.37%, BIOL is doing worse than 84.04% of the companies in the same industry.
BIOL's Return On Equity of -14222.30% is on the low side compared to the rest of the industry. BIOL is outperformed by 91.49% of its industry peers.
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROIC N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
BIOL Yearly ROA, ROE, ROICBIOL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 34.26%, BIOL is doing worse than 69.68% of the companies in the same industry.
In the last couple of years the Gross Margin of BIOL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BIOL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
BIOL Yearly Profit, Operating, Gross MarginsBIOL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

BIOL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIOL has been increased compared to 1 year ago.
BIOL has more shares outstanding than it did 5 years ago.
BIOL has a worse debt/assets ratio than last year.
BIOL Yearly Shares OutstandingBIOL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
BIOL Yearly Total Debt VS Total AssetsBIOL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

BIOL has an Altman-Z score of -13.20. This is a bad value and indicates that BIOL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -13.20, BIOL is doing worse than 83.51% of the companies in the same industry.
BIOL has a Debt/Equity ratio of 41.66. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 41.66, BIOL is doing worse than 91.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Altman-Z -13.2
ROIC/WACCN/A
WACC12.07%
BIOL Yearly LT Debt VS Equity VS FCFBIOL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

BIOL has a Current Ratio of 1.17. This is a normal value and indicates that BIOL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.17, BIOL is doing worse than 89.89% of the companies in the same industry.
BIOL has a Quick Ratio of 1.17. This is a bad value and indicates that BIOL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BIOL (0.64) is worse than 95.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.64
BIOL Yearly Current Assets VS Current LiabilitesBIOL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.89% over the past year.
The Revenue has been growing slightly by 0.13% in the past year.
The Revenue has been growing slightly by 1.27% on average over the past years.
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%

3.2 Future

Based on estimates for the next years, BIOL will show a very strong growth in Earnings Per Share. The EPS will grow by 41.31% on average per year.
Based on estimates for the next years, BIOL will show a small growth in Revenue. The Revenue will grow by 5.36% on average per year.
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIOL Yearly Revenue VS EstimatesBIOL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
BIOL Yearly EPS VS EstimatesBIOL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIOL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOL Price Earnings VS Forward Price EarningsBIOL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOL Per share dataBIOL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

BIOL's earnings are expected to grow with 41.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.31%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIOL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLASE INC

NASDAQ:BIOL (6/18/2024, 8:15:46 PM)

After market: 0.109 -0.02 (-15.5%)

0.129

-0.02 (-13.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2024-05-13/amc
Earnings (Next)08-08 2024-08-08/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners37.15%
Ins Owner Change0%
Market Cap4.31M
Analysts80
Price Target1.99 (1442.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.57%
Min EPS beat(2)-107.61%
Max EPS beat(2)32.47%
EPS beat(4)1
Avg EPS beat(4)-58.19%
Min EPS beat(4)-107.61%
Max EPS beat(4)32.47%
EPS beat(8)2
Avg EPS beat(8)-48.85%
EPS beat(12)4
Avg EPS beat(12)-28.48%
EPS beat(16)6
Avg EPS beat(16)-25.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.51%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-8.78%
Min Revenue beat(4)-23.29%
Max Revenue beat(4)-0.64%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)7
Avg Revenue beat(12)1.12%
Revenue beat(16)10
Avg Revenue beat(16)3.28%
PT rev (1m)-82.63%
PT rev (3m)-86.55%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)84.04%
EPS NY rev (1m)-37.5%
EPS NY rev (3m)76.15%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-8.58%
Revenue NY rev (1m)-1.61%
Revenue NY rev (3m)-4.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 16.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.25
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.46
BVpS0.01
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.26%
FCFM N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
F-Score3
Asset Turnover1.42
Health
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.8%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.64
Altman-Z -13.2
F-Score3
WACC12.07%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)202.36%
Cap/Sales(3y)4.06%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.89%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.18%
OCF growth 3YN/A
OCF growth 5YN/A